Acellular Stem Cell ECM via Triton X-100 Decellularization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for deriving extracellular matrices (ECMs) from pluripotent stem cells lack the ability to effectively recapitulate developmental cues and provide specific biological properties necessary for tissue engineering and regenerative medicine, particularly in terms of directing cell fate and lineage specification.
Innovation Solution
Acellular ECMs are prepared from 3-D aggregates or embryoid bodies of pluripotent stem cells through decellularization, using methods such as treatment with Triton X-100 and DNase, and can be cross-linked with genipin to enhance stability, allowing for the preservation of proteins like fibronectin, laminin, and glycosaminoglycans, which support cell proliferation and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If decellularization methods are applied to derive ECMs from pluripotent stem cells, then the ECMs can be used for tissue engineering and regenerative medicine, but the ability to effectively recapitulate developmental cues and provide specific biological properties is lacking
Solution Approach 1:
The patent employs multiple decellularization parameters including different detergents (Triton X-100, SDS, NP-40), enzymes (DNase I, proteinase K), and treatment durations to optimize ECM derivation. By systematically varying these parameters, the method achieves effective cell removal while preserving developmental cues and biological properties essential for tissue engineering applications
Solution Approach 2:
The patent utilizes composite decellularization approaches combining chemical detergents with enzymatic treatments. This composite method leverages the complementary actions of different agents to achieve thorough decellularization while maintaining the integrity of ECM proteins and growth factors, thereby preserving specific biological properties
2Reliability
If 3-D aggregates or embryoid bodies are used as starting material, then the ECMs can support cell proliferation and differentiation, but the manufacturing complexity increases
Solution Approach 1:
The patent prepares 3-D aggregates or embryoid bodies as pre-formed starting materials before decellularization. This preliminary structuring of stem cells into organized 3-D configurations ensures that the resulting ECMs contain properly organized developmental cues and extracellular matrix architecture, which are essential for supporting cell proliferation and differentiation in subsequent applications
Solution Approach 2:
The patent maintains spatial heterogeneity within the 3-D aggregates by preserving local ECM protein distributions and growth factor gradients during decellularization. This local quality preservation ensures that region-specific developmental cues are retained in the derived ECMs, enabling them to direct specific cell fate decisions and support tissue-specific differentiation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The decellularized ECMs effectively recapitulate developmental cues, supporting specific biological properties that direct stem cell fate, enhance cell proliferation, and promote differentiation into specific germ layers, offering improved potential for tissue engineering and regenerative applications.
Implementation Method 1
treatment with Triton X-100 and DNase
Implementation Method 2
treatment with Triton X-100 and DNase
Implementation Method 3
cross-linked with genipin to enhance stability
Data Source
AI summary
The subject invention pertains to acellular extracellular matrix (ECM) and methods for preparing it. In one embodiment, the ECM is prepared from 3-D aggregates of pluripotent stem cells or from embryoid bodies. In one embodiment, the ECM is in the form of acellular microspheres. The stem cells used in the present invention can be embryonic stem cells (ESC). In a specific embodiment, the stem cells or embryoid bodies are from human. The ECM of the invention can be mass produced using PSC aggregates or embryoid bodies in large scale bioreactors. The acellular ECM produced using the present invention can be used for injection into a person or animal to regenerate tissue and/or treat a disease or condition. A method of the invention comprises growing stem cells in suspension culture as aggregates, e.g., in a bioreactor. Acellular ECM is then prepared from the cell aggregates by decellularization. In a specific embodiment, a decellularization reagent comprising Triton X-100 is used, followed by treatment with a DNase.